Safety and Immunogenicity of BNT-162b2 versus Chadox1 Vaccine in Solid Organ Transplant Recipients: Prospective Study

ABSTRACT

Purpose: Data showed seroconversion after different SARS-CoV-2 vaccination platforms might yield diminished response in transplant recipients. However, it is unknown whether different vaccination platforms could offer a specific grade of protection against SARS-CoV-2. Method(s) we prospectively studied adult kidney & liver recipients who received who had no previous COVID-19 infection, and received either ChAdOx1 or BNT- 162b2 vaccines between January 2021 to September 2021, with an assessment of IgM/IgG spike (S) antibodies. Result(s) Our cohort is composed of kidney (n=235) or liver (n=217) patients, who have received either ChAdOx1 (N=157) or BNT-162b2 (n=295). The response was higher with mRNA vaccine. Unresponsiveness is found to be mainly linked to diabetes and older age. Side effects were similar to those reported in clinical trials. Conclusion(s) mRNA vaccines might elicit a higher humoral immunity response as compared with ChAdOx1 in immunosuppressed transplant patients.